EP2603521A4 - Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof - Google Patents

Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof

Info

Publication number
EP2603521A4
EP2603521A4 EP11817134.7A EP11817134A EP2603521A4 EP 2603521 A4 EP2603521 A4 EP 2603521A4 EP 11817134 A EP11817134 A EP 11817134A EP 2603521 A4 EP2603521 A4 EP 2603521A4
Authority
EP
European Patent Office
Prior art keywords
growth factor
factor receptor
fibroblast growth
antibody molecules
oncogenic isoforms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11817134.7A
Other languages
German (de)
French (fr)
Other versions
EP2603521A2 (en
Inventor
Xiao-Jia Chang
Ullrich S Schwertschlag
Katherine Jane Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ATTOGEN Inc
Original Assignee
ATTOGEN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ATTOGEN Inc filed Critical ATTOGEN Inc
Publication of EP2603521A2 publication Critical patent/EP2603521A2/en
Publication of EP2603521A4 publication Critical patent/EP2603521A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP11817134.7A 2010-08-12 2011-08-12 Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof Withdrawn EP2603521A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307210P 2010-08-12 2010-08-12
PCT/US2011/047650 WO2012021841A2 (en) 2010-08-12 2011-08-12 Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof

Publications (2)

Publication Number Publication Date
EP2603521A2 EP2603521A2 (en) 2013-06-19
EP2603521A4 true EP2603521A4 (en) 2014-10-01

Family

ID=45568223

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11817134.7A Withdrawn EP2603521A4 (en) 2010-08-12 2011-08-12 Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof

Country Status (3)

Country Link
EP (1) EP2603521A4 (en)
CN (1) CN103201287B (en)
WO (1) WO2012021841A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
KR20100132998A (en) * 2008-04-04 2010-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
JP2013529076A (en) 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド Anti-FGFR2 antibody
JP6188681B2 (en) 2012-04-09 2017-08-30 第一三共株式会社 Anti-FGFR2 antibody
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
ES2719103T3 (en) 2013-08-01 2019-07-08 Five Prime Therapeutics Inc Afucosylated anti-FGFR2IIIB antibodies
WO2016171107A1 (en) * 2015-04-20 2016-10-27 第一三共株式会社 Detection of fgfr2
TWI791422B (en) 2015-11-23 2023-02-11 美商戊瑞治療有限公司 Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
CN107513106A (en) * 2016-06-17 2017-12-26 艾托金生物医药（苏州）有限公司 Anti- FGFR2-IIIc monoclonal antibodies, hybridoma cell strain and application
US20190204326A1 (en) * 2016-09-27 2019-07-04 The University Of The Highlands And Islands Antigen biomarkers
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
KR102539445B1 (en) * 2020-11-25 2023-06-05 (주)케어젠 Peptide Having Activity of Protecting Cell Damage From Particulate Matter and Uses Thereof
CN113150135B (en) * 2021-04-14 2022-09-20 中山大学 Neutralizing antibodies against novel coronavirus receptor binding domains and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100105A2 (en) * 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2377252C2 (en) * 2003-07-22 2009-12-27 Шеринг Акциенгезельшафт Rg1 antibodies and application thereof
WO2006121207A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
CA2657953A1 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
EP2020419A1 (en) * 2007-07-31 2009-02-04 Bayer Schering Pharma Aktiengesellschaft Anti ephB4 antibody fragments
ES2770134T3 (en) * 2008-11-07 2020-06-30 Galaxy Biotech Llc Monoclonal antibodies to the fibroblast growth factor receptor 2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009100105A2 (en) * 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof

Also Published As

Publication number Publication date
CN103201287B (en) 2016-04-13
WO2012021841A3 (en) 2012-06-14
CN103201287A (en) 2013-07-10
EP2603521A2 (en) 2013-06-19
WO2012021841A2 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
EP2603521A4 (en) Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
HK1244496A1 (en) Antibodies to muc16 and methods of use thereof
HK1211607A1 (en) Chimeric fibroblast growth factor 21 proteins and methods of use 21
ZA201303803B (en) Humanized antibodies to liv-1 and use of same to treat cancer
HK1249533A1 (en) Multimeric il-15 soluble fusion molecules and methods of making and using same
EP2543060A4 (en) Systems and methods for application of optical materials to optical elements
EP2632490A4 (en) Novel egfr-binding molecules and immunoconjugates thereof
GB201002249D0 (en) Improvements in or relating to methods of manufacture
EP2582729A4 (en) Anti-axl antibodies and methods of use
EP2638149A4 (en) Immortalization of epithelial cells and methods of use
HK1202800A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins 21
HK1209060A1 (en) Antibodies to endoplasmin and their use
IL232950A0 (en) Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
EP2558496A4 (en) Anti-polyubiquitin antibodies and methods of use
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
HK1189501A1 (en) Antibody compositions and methods of use
IL229748A0 (en) Binding compounds to human ß1-adrenoreceptor (ß1-ar)and their use in the measurement of auto-anti-ßa1-ar antibodies
IL225494A0 (en) Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity
EP2538935A4 (en) Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine
EP2603459A4 (en) Synthesis of stannane and deuterostannane
HUP1100092A2 (en) Arrangement for production and using of biogas
TWM386327U (en) Girder structure made of bamboo
TWM386067U (en) Structure to make the top of van higher and to reinforce the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130307

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140828

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20140822BHEP

Ipc: C07K 16/00 20060101AFI20140822BHEP

Ipc: C07K 16/28 20060101ALI20140822BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150303